Quantcast
Home > Quotes > CDTX

Cidara Therapeutics, Inc. Common Stock (CDTX) Quote & Summary Data

CDTX 
$3.89
*  
0.01
0.26%
Get CDTX Alerts
*Delayed - data as of Nov. 16, 2018  -  Find a broker to begin trading CDTX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 3.99 / $ 3.83
Share Volume
61,043
50 Day Avg. Daily Volume
76,873
Previous Close
$ 3.88
52 Week High / Low
$ 8.55 / $ 3.36
Market Cap
107,953,067
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
61,043
50 Day Avg. Daily Volume:
76,873

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.11

Trading Range

The current last sale of $3.89 is 15.77% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.99 $ 8.55
 Low: $ 3.83 $ 3.36

Company Description (as filed with the SEC)

We are a biotechnology company focused on the discovery, development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. We are developing a balanced pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Our lead product candidate is rezafungin acetate, formerly known as CD101 IV, an intravenous formulation of a novel echinocandin. Rezafungin acetate has been approved as the international nonproprietary name, or INN, for CD101 by the World Health Organization, and as a United States Adopted Name, or USAN, for CD101 by the USAN Council. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious, invasive fungal infections.  ... More ...  


Risk Grade

Where does CDTX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 3.83
Open Date:
Nov. 16, 2018
Close Price:
$ 3.88
Close Date:
Nov. 16, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x